Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery Platform
Sponsor : Metaba
Deal Size : Inapplicable
Deal Type : Inapplicable
Metaba, MAX BioPharma Achieve Key Milestone on Next-Gen Oxysterol-Based Antibiotics
Details : Company is focused on developing oxysterol-based drug candidates targeting bacterial infections like tuberculosis, urinary tract infections, Lyme disease and MRSA.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 20, 2025
Lead Product(s) : Undisclosed,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery Platform
Sponsor : Metaba
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oxysterol,Inapplicable
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MAX BioPharma Shares Updates On Anti-Inflammatory Oxysterol Drug Development
Details : Oxy210 (oxysterol) is being evaluating in the early-stage clinical trial studies for the treatment of patients suffering from non-alcoholic steatohepatitis.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 24, 2024
Lead Product(s) : Oxysterol,Inapplicable
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oxysterol,Inapplicable
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Preclinical
Recipient : Metaba
Deal Size : Undisclosed
Deal Type : Collaboration
MAX BioPharma and Metaba Announce Collaboration on Metabolomics Studies
Details : The collaboration focuses on developing Oxy210 (oxysterol), a small-molecule antifibrotic, evaluated in preclinical studies for non-alcoholic steatohepatitis and pulmonary fibrosis.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 26, 2024
Lead Product(s) : Oxysterol,Inapplicable
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Preclinical
Recipient : Metaba
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Oxysterol,Inapplicable
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MAX BioPharma Announces Key Update to its Liver Fibrosis Program
Details : Oxy210 was found to significantly inhibit development of fibrosis in a humanized mouse model of NASH that involves progressive inflammation, fat deposition and fibrosis in the livers of these mice.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 03, 2020
Lead Product(s) : Oxysterol,Inapplicable
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable